Franklin Resources Inc. Sells 52,093 Shares of Jazz Pharmaceuticals PLC $JAZZ

Franklin Resources Inc. reduced its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 6.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 706,634 shares of the specialty pharmaceutical company’s stock after selling 52,093 shares during the quarter. Franklin Resources Inc. owned 1.16% of Jazz Pharmaceuticals worth $74,988,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of JAZZ. LSV Asset Management boosted its stake in Jazz Pharmaceuticals by 3.6% in the second quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock worth $271,003,000 after buying an additional 87,576 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Jazz Pharmaceuticals by 14.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock worth $289,066,000 after acquiring an additional 293,360 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Jazz Pharmaceuticals by 3.6% during the second quarter. JPMorgan Chase & Co. now owns 1,721,294 shares of the specialty pharmaceutical company’s stock worth $182,664,000 after acquiring an additional 59,252 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 41.7% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock worth $165,245,000 after acquiring an additional 391,660 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Jazz Pharmaceuticals by 1.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,171,755 shares of the specialty pharmaceutical company’s stock valued at $124,366,000 after purchasing an additional 16,757 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Heather Ann Mcsharry sold 3,415 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $177.78, for a total transaction of $607,118.70. Following the transaction, the director directly owned 20,449 shares of the company’s stock, valued at approximately $3,635,423.22. The trade was a 14.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Robert Iannone sold 7,159 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $168.26, for a total value of $1,204,573.34. Following the completion of the sale, the executive vice president directly owned 72,628 shares of the company’s stock, valued at $12,220,387.28. The trade was a 8.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 50,893 shares of company stock valued at $8,559,699. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $180.90 on Tuesday. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The company has a 50-day moving average price of $139.97 and a 200-day moving average price of $123.16. The company has a market cap of $10.99 billion, a price-to-earnings ratio of -26.88, a price-to-earnings-growth ratio of 8.49 and a beta of 0.29. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $182.99.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.87 by $2.26. The company had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.Jazz Pharmaceuticals’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the firm earned $6.54 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. As a group, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on JAZZ. Truist Financial lifted their target price on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Robert W. Baird upped their price target on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a research report on Tuesday, November 18th. Wells Fargo & Company lifted their price objective on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Zacks Research raised Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Finally, Royal Bank Of Canada set a $194.00 price target on Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research report on Monday, November 17th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $195.67.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.